A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.
* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.
‡ In addition to the above programs, AMJEVITA™/AMGEVITA™ and MVASI™ have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). KANJINTI™ has been approved by the EC and we have refiled our BLA with the FDA. We are also pursuing other biosimilar product candidates in earlier-stage clinical development.